A Randomized, Double-blind, Placebo-controlled, Phase 2

Project: Research project

Description

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Allisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
StatusActive
Effective start/end date3/17/143/29/20

Funding

  • MILLENNIUM PHARMACEUTICALS, INC.

Fingerprint

Small Cell Lung Carcinoma
Cell- and Tissue-Based Therapy
Paclitaxel
Lung Neoplasms
Placebos
Clinical Trials
MLN 8237
Therapeutics